As PRISMAP looks to make a new generation of radionuclides easily accessible to researchers, it is vital that any pre-clinical and clinical research is underpinned by accurate and reproducible measurements of activity and dosimetry. In the clinical setting these measurements are typically performed using a radionuclide calibrator before administration to a patient, with traceability to a national metrology institute such as the National Physical Laboratory (UK) or the Institute of Radiation Physics (Switzerland). This traceability comes through the primary standardisation of activity and underpins all clinical use of any radiopharmaceutical. To this end, the translational data generation work package (WP11) will seek to provide this traceability for the novel radionuclides being generated by the PRISMAP consortium and disseminate these standards to the wider community. Alongside this development, accurate nuclear decay data will be determined to provide confidence in this fundamental data. A challenge of molecular radiotherapy is the understanding of the dose delivered at a cellular level and the biological effect of the emissions of a radionuclide to tumour cells. To improve our understanding, Riga Technical University (Lativia) will investigate the doses absorbed from the emissions from the radioactive decay of radionuclides using nano-dosimeters. The University of Oslo will look at developing a traceable link of the activity standards of the PRISMAP radionuclides to their relative biological effectiveness through the dose response.